The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders
Abstract
OBJECTIVE: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). METHOD: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/day. Repetitive behaviors were measured with the compulsion subscale of the Yale-Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. RESULTS: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. CONCLUSIONS: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A few studies have also focused on the hypothesis that, at the level of neural circuits, ASD may result from excessive excitation or insufficient inhibition 213 , with some promising but inconclusive results for medicines that target the GABAergic system 214 .”
From Autism spectrum disorder (2020) · cites this paper as [213]
In the citing paper
“increased rates of behavioral activation, impulsiveness, and stereotypy have been observed in studies examining the use of SSRIs among patients with ASD for the treatment of restricted and repetitive behaviors [118].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [118]
In the citing paper
“Some trials of SSRIs evaluated depression as a secondary outcome measure, but they did not recruit for clinically significant depression in their participant cohort [118].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [118]
Citations
Cites
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Adult outcome for children with autism
Howlin, P., Goode, S., Hutton, J., & Rutter, M. (2004) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2004.00215.x · Cited by 1,813
Autism From 2 to 9 Years of Age
Lord, C., Risi, S., DiLavore, P. S., Shulman, C., Thurm, A., & Pickles, A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.694 · Cited by 973
The antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Mathur, R. (2004) · Drug Screening Methods · doi:10.5005/jp/books/10243_6 · Cited by 665
A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder
McDougle, C. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110037005 · Cited by 556
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Self-citationA Five to Fifteen Year Follow-Up Study of Infantile Psychosis: II. Social and Behavioural Outcome
Rutter, M., Greenfeld, D., & Lockyer, L. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1183 · Cited by 476
Research works printed but not linked: 2
- 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9 · doi:10.1002/1531-8249(199903)45:3<287::aid-ana3>3.0.co;2-9
- Aman MG, 1985, Am J Ment Defic, 89, 485
Cited by
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
The serotonin system in autism spectrum disorder: From biomarker to animal models
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.010 · Cited by 531
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub3 · Cited by 415
The Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
Metadata
- Authors
- Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., Wasserman, S., Swanson, E., & Settipani, C.
- Affiliations
- Albert Einstein College of Medicine (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2012-03
- Volume
- 169
- Issue
- 3
- Pages
- 292-299
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2035017299
- Cited by
- 224
- References
- 25
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 18 · 2023: 15 · 2022: 20 · 2021: 13 · 2020: 13 · 2019: 17 · 2018: 18 · 2017: 14 · 2016: 12 · 2015: 21 · 2014: 25 · 2013: 16 · 2012: 6
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (U54MH066673, 1U54 MH-066673)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- fluoxetine, autism spectrum disorder, autistic adults, repetitive behavior, obsessive-compulsive symptoms, Yale-Brown Obsessive Compulsive Scale, Clinical Global Impression Scale, selective serotonin reuptake inhibitors, treatment response, drug tolerability
- MeSH terms
- Adolescent, Adult, Child, Child Development Disorders, Pervasive, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Obsessive Behavior, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Stereotypic Movement Disorder, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders. https://app.cochat.ai/papers/10.1176/appi.ajp.2011.10050764
- The paper
- Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., Wasserman, S., Swanson, E., & Settipani, C. (2012). A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2011.10050764
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.